The delegate's final decision is to amend the Poisons Standard to include semaglutide in Schedule 4 as follows:
Schedule 4 - New Entry
Index - New Entry
1 June 2019
The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the delegate for the decision include:
the risks and benefits of the use of a substance:
It is a new biological entity with no clinical or marketing experience in Australia.
the purposes for which a substance is to be used and the extent of use of a substance:
Semaglutide is a long-acting glucagon like peptide-1 (GLP-1) receptor agonist (GLP=1RA), with suggested indication for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
in addition to other medicinal products for the treatment of type 2 diabetes
the toxicity of a substance:
No known major/serious toxicities
the dosage, formulation, labelling, packaging and presentation of a substance:
No specific requirements over existing regulations and guidelines
the potential for abuse of a substance:
any other matters that the Secretary considers necessary to protect public health:
The delegate of the Secretary proposed to amend the Poisons Standard with respect to semaglutide, a new chemical entity (NCE) for a human therapeutic medicine.
Semaglutide is not specifically scheduled and is not captured by any entry in the Poisons Standard.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.